A Prospective Randomized Open-label Interventional Study to Investigate the Efficacy of Complement C5 Inhibition With Zilucoplan® in Improving Oxygenation and Short-and Longterm Outcome of COVID19 Patients With Acute Hypoxic Respiratory Failure
Latest Information Update: 18 Sep 2023
At a glance
- Drugs Zilucoplan (Primary)
- Indications Acute hypoxia; COVID 2019 infections; Respiratory insufficiency
- Focus Therapeutic Use
- Acronyms ZILU-COV
- 01 Jul 2021 Status changed from active, no longer recruiting to completed.
- 01 Mar 2021 Planned End Date changed from 1 Apr 2021 to 30 Apr 2021.
- 18 Dec 2020 Planned End Date changed from 1 Sep 2021 to 1 Apr 2021.